Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma

PRIMARY OBJECTIVE: I. To determine the seroprotection and seroconversion rates after influenza or SARS-CoV2 vaccination in patients with lymphoma receiving active treatment or in follow up observation. SECONDARY OBJECTIVES: I. To characterize virus-specific plasmablasts and memory B cells after vaccination in patients with lymphoma receiving active treatment or in follow up observation. II. To investigate the longevity of viral-specific humoral immunity to influenza virus in patients with lymphoma receiving active treatment or in follow up observation. III. To assess the timing and strength of the peak immune response to vaccination. IV. To assess the effect of different lymphomas and treatment modalities in the immune response to vaccination. OUTLINE: Patients receive seasonal inactivated influenza vaccine intramuscularly (IM) at day 0. After completion of study treatment, patients are followed up at days 7, 28, 90, 180, and 365.